La vendita allo scoperto per Revelation Biosciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Revelation Biosciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Revelation Biosciences (NASDAQ:REVBW) Azioni, Report sulle vendite allo scoperto

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Revelation Biosciences Inc

System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.29) by 17.24 percent. The company reported quarterly sales of $88.832 million which beat the analyst consensus estimate of $86.629 million by 2.54 percent. This is a 1.15 percent increase over sales of $87.818 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

System1 Q3 2024 GAAP EPS $(0.34) Misses $(0.29) Estimate, Sales $88.832M Beat $86.629M Estimate

Mexco Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) reported quarterly earnings of $0.15 per share. This is a 25 percent increase over earnings of $0.12 per share from the same period last year. The company reported $1.75 million in sales this quarter. This is a 24.32 percent increase over sales of $1.41 million the same period last year.

Mexco Energy Q2 EPS $0.15 Up From $0.12 YoY, Sales $1.75M Up From $1.41M YoY

WIIM

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue above estimates.

RXST

RxSight shares are trading lower. The company reported Q3 financial results.

EPRX

Eupraxia Pharmaceuticals Reports Q3 Net Income Of $(6.0)M, Down From $(4.9)M Loss Last Year

TELA Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELA#NASDAQ">TELA</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 6.67 percent increase over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $18.957 million which beat the analyst consensus estimate of $18.852 million by 0.56 percent. This is a 25.94 percent increase over sales of $15.052 million the same period last year.

TELA

TELA Bio Q3 2024 GAAP EPS $(0.42) Misses $(0.41) Estimate, Sales $18.957M Beat $18.852M Estimate

Tuscows Q3 Revenue $92.297M Up From 86.971M YoY

LCID

Lucid Group shares are trading higher after the company reported better-than-expected Q3 financial results.

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) .

Guidance

PBYI

Puma Biotechnology expects Q424 Net Product Revenue: $46M-$48M; FY2024: $187M-$190M (Prev. $183M-$190M).

KTOS

Kratos Defense & Security shares are trading lower after the company reported worse-than-expected Q3 revenue results.

Offerings

Valley National Bancorp Announces Proposed Common Stock Offering

Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.08 by 112.5 percent. The company reported quarterly sales of $330.399 million which missed the analyst consensus estimate of $382.239 million by 13.56 percent. This is a 17.46 percent decrease over sales of $400.268 million the same period last year.

Bloom Energy Q3 2024 Adj. EPS $(0.01) Misses $0.08 Estimate, Sales $330.399M Miss $382.239M Estimate

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2025 GAAP EPS guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 analyst estimate..

Chesapeake Utilities Affirms FY2025 GAAP EPS Guidance from $6.15-6.35 to $6.15-6.35 vs $6.25 Est

CPRI

Capri Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.

Chesapeake Utilities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPK#NYSE">CPK</a>) affirms FY2024 GAAP EPS guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 analyst estimate..

Chesapeake Utilities Affirms FY2024 GAAP EPS Guidance from $5.33-5.45 to $5.33-5.45 vs $5.39 Est

Buybacks

TRIN

Trinity Capital Inc. Announces Stock Repurchase Program Of Up To $30M

FLYW

Flywire shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 18.37 percent increase over losses of $(0.49) per share from the same period last year.

Vor Biopharma Q3 EPS $(0.40), Inline

Ovintiv Sees FY24 Capital Investment $2.275B-$2.325B

Farmer Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. The company reported quarterly sales of $85.066 million which beat the analyst consensus estimate of $84.100 million by 1.15 percent. This is a 3.88 percent increase over sales of $81.888 million the same period last year.

Comments

Revelation Biosciences

Vendite allo scoperto

Revelation Biosciences (NASDAQ:REVBW) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO